A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman et al. · Nature · 2011 · 1.4K citations

Medicine, Molecular Biology, Oncology +9

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Meghna Das Thakur, Fernando Salangsang, Allison Landman et al. · Nature · 2013 · 735 citations

Medicine, Oncology, Pharmacology +16

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Jenny Lee, Georgina V. Long, Stephanie Boyd et al. · Annals of Oncology · 2017 · 328 citations · Full text

Medicine, Immunology, Oncology +16

ctDNA monitoring using patient-specific sequencing and integration of variant reads

Jonathan C. M. Wan, Katrin Heider, Davina Gale et al. · Science Translational Medicine · 2020 · 200 citations · Full text

Life Sciences, Genetics, Molecular Biology +17